What is MaxCyte?
MaxCyte operates at the forefront of clinical-stage cell-based therapies and life sciences, leveraging its proprietary cell engineering platform. The company is dedicated to bringing the transformative potential of cell-based medicine to patients suffering from conditions with limited treatment options. Its technology is designed to facilitate the delivery of advanced cellular therapies, positioning MaxCyte as a key innovator in a rapidly evolving healthcare sector.
How much funding has MaxCyte raised?
MaxCyte has raised a total of $77.3M across 6 funding rounds:
Series A
$8M
Series B
$10.7M
Stock Offering
$14.4M
Share Placement
$12.3M
Debt
$1M
Share Placement
$30.9M
Series A (2003): $8M with participation from Undisclosed
Series B (2004): $10.7M led by Intersouth Partners, Harbert Venture Partners, and Tall Oaks Capital
Stock Issuance/Offering (2016): $14.4M supported by Undisclosed
Share Placement (2019): $12.4M featuring Undisclosed
Debt (2020): $1M backed by PPP
Share Placement (2020): $30.9M with participation from Sofinnova Crossover and Casdin Capital
Key Investors in MaxCyte
Intersouth Partners
Intersouth Partners is a venture capital firm known for investing in early-stage and growth-stage companies, likely focusing on technology and life sciences sectors.
Harbert Venture Partners
Harbert Venture Partners, part of Harbert Management Corporation, specializes in private equity investments, with a focus on middle-market and later-stage companies in technology and life sciences.
Tall Oaks Capital
Tall Oaks Capital is an investment firm that supports seed and early-stage companies, particularly those with strong management, market potential, and proprietary technology, often in the Mid-Atlantic and Southeastern U.S.
What's next for MaxCyte?
With the infusion of $30.9M in its latest strategic investment, MaxCyte is poised for accelerated growth and further development of its groundbreaking cell engineering platform. This enterprise-level funding is expected to fuel advancements in clinical trials, expand manufacturing capabilities, and potentially broaden the therapeutic applications of its technology. The company's trajectory suggests a focus on scaling operations to meet the increasing demand for innovative cell-based treatments, reinforcing its commitment to addressing critical healthcare challenges.
See full MaxCyte company page
